Canada Markets close in 4 hrs 29 mins

LLY Feb 2023 290.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
21.500.00 (0.00%)
As of 09:39AM EST. Market open.
Full screen
Previous Close21.50
OpenN/A
Bid20.45
Ask23.35
Strike290.00
Expire Date2023-02-17
Day's Range21.50 - 21.50
Contract RangeN/A
VolumeN/A
Open Interest216
  • Simply Wall St.

    Eli Lilly and Company (NYSE:LLY) is largely controlled by institutional shareholders who own 85% of the company

    Every investor in Eli Lilly and Company ( NYSE:LLY ) should be aware of the most powerful shareholder groups. With 85...

  • Reuters

    Drug companies face COVID cliff in 2023 as sales set to plummet

    Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.

  • Reuters

    FOCUS-Drug companies face COVID cliff in 2023 as sales set to plummet

    Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE , Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.